Congestion - that bunged up, stuffy nose ­feeling - is usually a fleeting symptom of a cold which lasts for around a week and ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

Sanofi & Regeneron’s Dupixent pivotal study meets all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis: Paris Monday, November 10, ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the ...

Females have a higher odds of chronic rhinosinusitis (CRS) without nasal polyps than men, according to a study published online Oct. 23 in JAMA Otolaryngology-Head & Neck Surgery. Richard G. Chiu, ...

The U.S. Food and Drug Administration approved Tezspire (tezepelumab-ekko; Amgen) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in ...

Findings showed treatment with tezepelumab significantly reduced the size of nasal polyps and nasal congestion compared with placebo. The Food and Drug Administration (FDA) has approved Tezspire ® ...

Approval broadens indication for TEZSPIRE to a second disease characterized by epithelial-driven inflammation WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab -ekko) ...

About Chronic Rhinosinusitis with Nasal Polyps (CRSwNP [nasal polyps]) CRSwNP is a complex inflammatory disorder characterized by persistent inflammation of the nasal mucosa accompanied by benign ...